CD99 is highly expressed in T cell acute lymphoblastic leukemia (T-ALL), a type of cancer. One promising treatment involves a mouse monoclonal antibody against CD99 called mAb MT99/3, which binds to CD99 and kills T-ALL cells without harming healthy cells. Researchers have now created a version of this antibody that is more suitable for humans, called Humanized Anti-CD99 Antibody, which works similarly to the original. This humanized antibody can target cancer cells specifically, without affecting normal peripheral blood mononuclear cells, offering hope for safer and more effective treatments for certain blood cancers.
Funding
Chiang Mai University (TGCMU2566P004) and Fundamental Fund 2024
Original Paper
Title of original paper: Exploring the Biological Activity of a Humanized Anti-CD99 ScFv and Antibody for Targeting T Cell Malignancies
Journal: Biomolecules
DOI: https://doi.org/10.3390/biom14111422